Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Manufacturers of insulin products for diabetes therapy have long sought ways to modify the absorption rate of exogenously administered insulins in an effort to better reproduce the naturally occurring pharmacokinetics of endogenous insulin secretion. Several mechanisms of protraction have been used in pursuit of a basal insulin, for which a low injection frequency would provide tolerable and reproducible glucose control; these mechanisms have met with varying degrees of success. Before the advent of recombinant DNA technology, development focused on modifications to the formulation that increased insulin self‐association, such as supplementation with zinc or the development of preformed precipitates using protamine. Indeed, NPH insulin remains widely used today despite a frequent need for a twice‐daily dosing and a relatively high incidence of hypoglycaemia. The early insulin analogues used post‐injection precipitation (insulin glargine U100 ) or dimerization and albumin binding (insulin detemir) as methods of increasing therapeutic duration. These products approached a 24‐hour glucose‐lowering effect with decreased variability in insulin action. Newer basal insulin analogues have used up‐concentration in addition to precipitation (insulin glargine U300 ), and multihexamer formation in addition to albumin binding (insulin degludec), to further increase duration of action and/or decrease the day‐to‐day variability of the glucose‐lowering profile. Clinically, the major advantage of these recent analogues has been a reduction in hypoglycaemia with similar glycated haemoglobin control when compared with earlier products. Future therapies may bring clinical benefits through hepato‐preferential insulin receptor binding or very long durations of action, perhaps enabling once‐weekly administration and the potential for further clinical benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Self-citationRatner, R. E., Hirsch, I. B., Neifing, J. L., Garg, S. K., Mecca, T. E., & Wilson, C. A. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.639 · Cited by 455
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448
Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008) · Diabetologia · doi:10.1007/s00125-007-0911-x · Cited by 447
Becker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407
Self-citationHeise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397
Self-citationRatner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346 · cited 7×
“A prespecified meta-analysis of patient-level data revealed a significantly lower risk of overall con- firmed (17% lower) and nocturnal confirmed hypoglycaemic events (32% lower) for patients with type 2 diabetes receiving IDeg U100 versus IGlar U100.”
BackgroundSelf-citationKlein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L., & Heise, T. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00685.x · Cited by 251
Self-citationA Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Haahr, H., & Heise, T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0165-y · Cited by 226 · cited 1×
“however, the zinc concentration of IDeg U200 has been optimized to increase its bioequivalence to the U100 formulation.(77) An ongoing, randomized, double-blind, multiple-dose, 2-period”
MethodSelf-citationMeneghini, L., Atkin, S. L., Gough, S. C. L., Raz, I., Blonde, L., Shestakova, M., Bain, S., Johansen, T., Begtrup, K., Birkeland, K. I., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1668 · Cited by 226
Mathieu, C., Hollander, P., Miranda-Palma, B., Cooper, J., Franek, E., Russell-Jones, D., Larsen, J., Tamer, S. C., Bain, S. C., & on behalf of the NN1250-3770 (BEGIN: Flex T1) Trial Investigators (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3249 · Cited by 219
Self-citationGough, S. C. L., Bhargava, A., Jain, R., Mersebach, H., Rasmussen, S., & Bergenstal, R. M. (2013) · Diabetes Care · doi:10.2337/dc12-2329 · Cited by 150
de la Peña, A., Riddle, M., Morrow, L. A., Jiang, H. H., Linnebjerg, H., Scott, A., Win, K. M., Hompesch, M., Mace, K. F., Jacobson, J. G., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0721 · Cited by 125 · cited 1×
“Onset of action, however, remains similar such that dosing 30 minutes before mealtime is suitable for both concentrations.(68) This phenomenon, whereby”
BackgroundKorsatko, S., Deller, S., Koehler, G., Mader, J. K., Neubauer, K., Adrian, C. L., Thomsen, H., Haahr, H., & Pieber, T. R. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0096-7 · Cited by 89 · cited 1×
“(100 and 200 U/mL) are similar in terms of PK and PD characteristics.(74) In a post hoc analysis, the 90% CIs for area under the serum IDeg U100 and U200 concentration–time curves and maximum IDeg”
MethodInsulin Stacking Versus Therapeutic Accumulation: Understanding the Differences
Heise, T., & Meneghini, L. F. (2014) · Endocrine Practice · doi:10.4158/ep13090.ra · Cited by 87 · cited 2×
“This reduces waxing and waning of effect, thereby reducing the risk of hypoglycaemia.(58) It is also important to note, however, that a significant 27% relative”
BackgroundSelf-citationSteensgaard, D. B., Schluckebier, G., Strauss, H. M., Norrman, M., Thomsen, J. K., Friderichsen, A. V., Havelund, S., & Jonassen, I. (2013) · Biochemistry · doi:10.1021/bi3008609 · Cited by 86
Albright, E. S., Desmond, R., & Bell, D. S. H. (2004) · Diabetes Care · doi:10.2337/diacare.27.2.632 · Cited by 75
Cited by
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574
Identification of barriers to insulin therapy and approaches to overcoming them
Russell‐Jones, D., Pouwer, F., & Khunti, K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13132 · Cited by 238
Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review
Janež, A., Guja, C., Mitrakou, A., Lalic, N., Tankova, T., Czupryniak, L., Tabák, A. G., Prazny, M., Martinka, E., & Smircic-Duvnjak, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00743-7 · Cited by 177
Minimising hypoglycaemia in the real world: the challenge of insulin
Mathieu, C. (2021) · Diabetologia · doi:10.1007/s00125-020-05354-7 · Cited by 16
Self-citationKawaguchi, Y., Sawa, J., Hamai, C., Nishimura, Y., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13038 · Cited by 10
Metadata
- Authors
- Heise, T., & Mathieu, C.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-09-26
- Volume
- 19
- Issue
- 1
- Pages
- 3-12
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2520301979
- Cited by
- 106
- References
- 18
- FWCI
- 11.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.